7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan
Background. Ten-day concomitant therapy achieves a high eradication rate in Taiwan. Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear. Aim. To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/463985 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553418639540224 |
|---|---|
| author | Sung-Shuo Kao Wen-Chi Chen Ping-I Hsu Kwok-Hung Lai Hsien-Chung Yu Hui-Hwa Cheng Nan-Jing Peng Chiun-Ku Lin Hoi-Hung Chan Wei-Lun Tsai Huay-Min Wang Tzung-Jiun Tsai Kung-Hung Lin Feng-Woei Tsay |
| author_facet | Sung-Shuo Kao Wen-Chi Chen Ping-I Hsu Kwok-Hung Lai Hsien-Chung Yu Hui-Hwa Cheng Nan-Jing Peng Chiun-Ku Lin Hoi-Hung Chan Wei-Lun Tsai Huay-Min Wang Tzung-Jiun Tsai Kung-Hung Lin Feng-Woei Tsay |
| author_sort | Sung-Shuo Kao |
| collection | DOAJ |
| description | Background. Ten-day concomitant therapy achieves a high eradication rate in Taiwan. Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear. Aim. To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to investigate factors influencing the eradication outcome. Methods. From March 2008 to March 2012, 319 H. pylori-infected patients receiving a 7-day pantoprazole-containing concomitant regimen (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days) were included. Patients were asked to return at the second week to assess drug compliance and adverse effects. Repeated endoscopy or urea breath test was performed at 8 weeks after the end of eradication therapy. Results. The eradication rates according to intention-to-treat and per-protocol analyses were 93.7% (299/319) and 96.4% (297/308), respectively. Adverse events occurred in 13.2% (42/319) of the patients. The compliance rate was 98.4% (314/319). Multivariate analysis disclosed that poor compliance was the only independent factor influencing the efficacy of anti-H. pylori therapy with an odds ratio of 0.073 (95% confidence interval, 0.011–0.483).
Conclusion. 7-day concomitant therapy achieved a very high eradication rate for H. pylori infection in Taiwan. Drug compliance was the only clinical factor influencing treatment efficacy. |
| format | Article |
| id | doaj-art-b06a17019a794500b208efb90ce59b1c |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-b06a17019a794500b208efb90ce59b1c2025-02-03T05:54:04ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/4639854639857-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in TaiwanSung-Shuo Kao0Wen-Chi Chen1Ping-I Hsu2Kwok-Hung Lai3Hsien-Chung Yu4Hui-Hwa Cheng5Nan-Jing Peng6Chiun-Ku Lin7Hoi-Hung Chan8Wei-Lun Tsai9Huay-Min Wang10Tzung-Jiun Tsai11Kung-Hung Lin12Feng-Woei Tsay13Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDepartment of Pathology, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDepartment of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanBackground. Ten-day concomitant therapy achieves a high eradication rate in Taiwan. Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear. Aim. To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to investigate factors influencing the eradication outcome. Methods. From March 2008 to March 2012, 319 H. pylori-infected patients receiving a 7-day pantoprazole-containing concomitant regimen (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days) were included. Patients were asked to return at the second week to assess drug compliance and adverse effects. Repeated endoscopy or urea breath test was performed at 8 weeks after the end of eradication therapy. Results. The eradication rates according to intention-to-treat and per-protocol analyses were 93.7% (299/319) and 96.4% (297/308), respectively. Adverse events occurred in 13.2% (42/319) of the patients. The compliance rate was 98.4% (314/319). Multivariate analysis disclosed that poor compliance was the only independent factor influencing the efficacy of anti-H. pylori therapy with an odds ratio of 0.073 (95% confidence interval, 0.011–0.483). Conclusion. 7-day concomitant therapy achieved a very high eradication rate for H. pylori infection in Taiwan. Drug compliance was the only clinical factor influencing treatment efficacy.http://dx.doi.org/10.1155/2012/463985 |
| spellingShingle | Sung-Shuo Kao Wen-Chi Chen Ping-I Hsu Kwok-Hung Lai Hsien-Chung Yu Hui-Hwa Cheng Nan-Jing Peng Chiun-Ku Lin Hoi-Hung Chan Wei-Lun Tsai Huay-Min Wang Tzung-Jiun Tsai Kung-Hung Lin Feng-Woei Tsay 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan Gastroenterology Research and Practice |
| title | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan |
| title_full | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan |
| title_fullStr | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan |
| title_full_unstemmed | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan |
| title_short | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan |
| title_sort | 7 day nonbismuth containing concomitant therapy achieves a high eradication rate for helicobacter pylori in taiwan |
| url | http://dx.doi.org/10.1155/2012/463985 |
| work_keys_str_mv | AT sungshuokao 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT wenchichen 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT pingihsu 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT kwokhunglai 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT hsienchungyu 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT huihwacheng 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT nanjingpeng 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT chiunkulin 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT hoihungchan 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT weiluntsai 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT huayminwang 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT tzungjiuntsai 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT kunghunglin 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan AT fengwoeitsay 7daynonbismuthcontainingconcomitanttherapyachievesahigheradicationrateforhelicobacterpyloriintaiwan |